Communicable Disease Market: A BCC Research Overview

Publish Date: May 2019 | Category: Healthcare, Pharmaceuticals & Medical Devices | Publisher: BCC Research | Status: Publish

The global market for communicable disease should grow from $57.7 billion in 2019 to $69.4 billion by 2024 at a compound annual growth rate (CAGR) of 3.8% for the period of 2019-2024.

Report Scope:

The scope of this report is broad and covers therapeutics used in treatment of communicable diseases. The report highlights the current and future market potential of communicable diseases therapeutics and provides a detailed analysis of the competitive environment, regulations, epidemiology of communicable diseases, merger and acquisition, drivers, restraints, and pipeline drugs in the market. The report also covers market projections through 2024. 

The report details market shares of communicable diseases based on different disease indication. Based on disease indication the market is segmented into HIV, Hepatitis B&C, Herpes Simplex Virus, Influenza, Malaria, Tuberculosis, and Others.

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Spain, Italy, Japan, China and India. For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on product manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Report Includes:

- 23 data tables and 24 additional tables
- Detailed overview of the global market for communicable diseases within the healthcare industry
- Analyses of the global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024
- Regional analysis of the communicable disease market, covering North America, Europe, Asia-Pacific, South America and Middle East & Africa
- A look at the government regulations pertaining to drug developments for communicable diseases and pipeline analysis covering ongoing clinical trials and promising forthcoming therapies in late stage
- Discussion of competitive landscape, mergers and acquisitions of companies to enhance their product portfolio, and future commercial marketplace
- Comprehensive company profiles of major market players, including Abbott Laboratories, AbbVie Inc., GlaxoSmithKline Plc, Novartis AG and Pfizer Inc.

Summary

The global market for communicable disease was valued at REDACTED in 2018. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED to reach approximately REDACTED by 2024. The market is expected to grow during the forecast period owing to rising prevalence of sexually transmitted diseases, growing awareness regarding communicable diseases, development of novel therapies, and growing public and private partnership for research of new therapies.

The global communicable disease market is segmented based on disease indication and region.

North America is estimated to have the highest market share and the Asia-Pacific region is anticipated to have the highest growth rate during the forecast period. The increase in health care expenditure in the Asia-Pacific market, growing research and development activities, and increase in prevalence of STDs, HIV, and infectious diseases coupled with growing government initiative in creating awareness regarding communicable disease are the major factors augmenting the growth of communicable disease market in the Asia-Pacific region.

Table of Contents

Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology 
Geographic Breakdown
Analyst's Credentials
BCC Custom Research 
Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background
Disease Overview 
HIV
HIV Timeline and Milestones
HIV Life Cycle: Treatment and Mechanism of Action
HIV Prophylaxis
Epidemiology
Chlamydia
Epidemiology
Genital Herpes
Epidemiology
Gonorrhea
Epidemiology
Hepatitis A, B and C
Epidemiology
HPV
Syphilis
Epidemiology
Malaria
Incidence and Geographical Distribution
Tuberculosis
Incidence and Geographical Distribution
Influenza
Incidence and Mortality
Trichomoniasis
Scabies
Bacterial Vaginosis
Candidiasis 
Chancroid (Venereal Ulcers)
Pediculosis Pubis

Chapter 4 Market Dynamics
Market Drivers
Regional Awareness Program for Communicable Diseases
Development of Novel Therapies
Public Private Partnership
Global Program to Counter HIV
Increasing Prevalence of Communicable Diseases
Market Restraints
Social Stigma Associated with STD
High Cost of Treatment
Underestimating the Risk of Contracting the Disease
Lack of Prenatal Screenings for STD

Chapter 5 Market Breakdown by Disease Type
Global Market for Communicable Disease, by Disease Indication
HIV
Market Size and Forecast
Market Analysis
Hepatitis B&C
Market Size and Forecast
Market Analysis
Herpes Simplex Virus
Market Size and Forecast
Market Analysis
Influenza
Market Size and Forecast
Market Analysis
Malaria
Market Size and Forecast
Market Analysis
Tuberculosis
Market Size and Forecast
Market Analysis
Others
Market Size and Forecast
Market Analysis

Chapter 6 Market Breakdown by Region
Global Market for Communicable Disease, by Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Spain
Italy
Rest of Europe
Asia-Pacific
Japan
China
India
Rest of Asia-Pacific
South America
Middle East & Africa

Chapter 7 Pipeline Analysis
Overview
Hepatitis B and Hepatitis C
Herpes Simplex Virus
HIV/AIDS
Influenza A and Influenza B
Respiratory Syncytial Virus
Malaria
Tuberculosis
MERS
Hemorrhagic Fevers
Dengue
Ebola
Lassa fever
Marburg
Yellow Fever
Zika

Chapter 8 Regulation and Reimbursement
Regulations
U.S.
Europe
Japan
China
Pricing and Reimbursement
U.S.
Europe
Japan

Chapter 9 Competitive Landscape
Sexually Transmitted Disease Therapeutics: Global Competitor Analysis
Influenza Therapeutics: Global Competitor Analysis

Chapter 10 Company Profiles
ABBOTT LABORATORIES 
ABBVIE INC.
ASTRAZENECA/MEDIMMUNE
AUROBINDO PHARMA LTD.
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
BRISTOL-MYERS SQUIBB CO.
CIPLA INC.
DAIICHI SANKYO
GILEAD SCIENCES, INC.
GLAXOSMITHKLINE PLC
JANSSEN PHARMACEUTICALS, INC.
MERCK & CO., INC.
MITSUBISHI TANABE PHARMA CORP.
MYLAN LABORATORIES
NOVARTIS AG
PFIZER INC.
HOFFMANN-LA ROCHE INC.
SANOFI, SANOFI PASTEUR
SEQIRUS, A CSL COMPANY
VIIV HEALTHCARE

Chapter 11 Appendix: Acronyms

Choose License Type

Research Assistance

For Enquiries, Call :

+44-203-322-1521

Email : sales@trendsmarketresearch.com

Send Your Request